CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 971 enrolled
Drug / intervention
Influenza vaccine GSK2186877A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00772889
NCT00772889Phase 3Completed
CompareCT.gov

Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

GlaxoSmithKline·interventional·Posted Oct 15, 2008·Updated Jul 31, 2018

In Brief

A Phase 3 clinical trial evaluating Influenza vaccine GSK2186877A and GSK Biologicals' Fluarix™ for Influenza. Completed, enrolled 971 participants across 29 sites in 4 countries.

Detailed Summary

The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBelgium, Germany, Norway, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 15, 2008
Enrollment StartOct 9, 2008
Primary CompletionDec 15, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.7 years ago

Interventions

Influenza vaccine GSK2186877Abiological

One intramuscularly injection at Day 0

GSK Biologicals' Fluarix™biological

One intramuscularly injection at Day 0